Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Active Biotech on private placement
Mandate

Vinge has advised Active Biotech on private placement

February 03, 2011

Active Biotech AB (publ) (NASDAQ OMX Stockholm) has carried out a private placement of new shares of SEK 375 million directed towards international institutional investors and qualified investors in Sweden.

Vinge acted for Active Biotech. Vinge’s team consisted of Erik Sjöman and Christian Lindhé.

Related

Vinge has advised Investor in connection with acquisition of shares in EQT

 Vinge has advised Investor in connection with an acquisition of 12,500,000 shares in EQT AB from Wallenberg Investments for a total consideration of approximately SEK 3.5 billion.
October 19, 2026

Vinge has advised Oncopeptides in connection with a directed share issue

 Vinge has advised Oncopeptides in connection with a directed share issue, whereby Oncopeptides raises proceeds of SEK 100 million.
October 16, 2026

Vinge advises KGAL on its divestment of a Nordic wind portfolio to Enordic Evergreen

 Vinge has advised KGAL on the divestment of a Nordic onshore wind portfolio to Enordic Evergreen.
October 14, 2026